Abstract
BackgroundGolgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; however, its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. We examined GOLPH3 expression levels and relationship with survival in patients with PDAC to establish the significance of GOLPH3 in the development and progression of PDAC.MethodsReal-time qPCR and Western blotting were performed to analyze the expression levels of GOLPH3 mRNA and protein in paired PDAC tumor and adjacent non-tumor tissues. Immunohistochemistry was used to analyze the expression levels of GOLPH3 protein in paraffin-embedded tissues from 109 cases of PDAC. Univariate and multivariate analyses were performed to identify correlations between the immunohistochemical data for GOLPH3 expression and the clinicopathologic characteristics in PDAC.ResultsExpression levels of GOLPH3 mRNA and protein were upregulated in PDAC lesions compared to paired adjacent noncancerous tissues. Expression of GOLPH3 was significantly correlated with clinical stage (P = 0.006), T classification (P = 0.021), N classification (P = 0.049) and liver metastasis (P = 0.035). Patients with high GOLPH3 expression had shorter overall survival times compared to those with low GOLPH3 expression (P = 0.007). Multivariate analysis revealed that GOLPH3 overexpression was an independent prognostic factor in PDAC.ConclusionsOur findings suggest that GOLPH3 expression status may be a potential prognostic biomarker and therapeutic target in PCAC.
Highlights
Golgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; its role in pancreatic ductal adenocarcinoma (PDAC) is unknown
In this study we investigated and identified Golgi phosphoprotein 3 (GOLPH3) as potential prognostic and predictive marker associated with poor survival rates in PDAC
The histological grades and clinical stages were classified according the to the tumor-node-metastasis staging system for pancreatic cancer, as defined by the American Joint Committee on Cancer (AJCC)
Summary
Golgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. In this study we investigated and identified Golgi phosphoprotein 3 (GOLPH3) as potential prognostic and predictive marker associated with poor survival rates in PDAC. GOLPH3 enhances growth-factor induced mTOR signaling and modulate the response to rapamycin [19] Those investigations have uncovered some potential links of GOLPH3 with cellular function to tumorigenesis which is very important for us to further understand how this protein contritute to cancer pathology. We examined GOLPH3 expression in 109 cases of formalinfixed, paraffin-embedded (FFPE) tissue specimens of human PDAC, and performed univariate and multivariate analyses to correlate its expression levels with patient survival and clinicopathologic features in PDAC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
